Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Entry and Attachment Inhibitors
Ibalizumab-uiyk (Trogarzo, IBA)
Last Updated: December 24, 2019; Last Reviewed: December 24, 2019
Excerpt from Table 8
|Formulation||Dosing Recommendationsa||Use in Pregnancy|
||Standard Adult Dose:
PKs in Pregnancy:
|No data available, but placental transfer of IBA, a monoclonal antibody, is possible.
Insufficient data to assess for teratogenicity in humans.
|a Individual ARV drug doses may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Antiretroviral Guidelines, Appendix B, Table 10).
Key: ARV = antiretroviral; IBA = ibalizumab; IV = intravenous; PK = pharmacokinetic
- AIDSinfo Drug Database
- AIDSinfo Patient Materials: Preventing Mother-to-Child Transmission of HIV
- AIDSinfo Patient Materials: HIV Medicines During Pregnancy and Childbirth
- AIDSinfo Patient Materials: Protecting Baby from HIV
- AETC National HIV Curriculum
- How to Cite These Guidelines
- Perinatal Guidelines Archive